Your fact-checks will appear here
SNP in APOE increasing the risk of dementia
There is scattered scientific evidence that some marketed “relief formulas” or individual ingredients can affect biological pathways relevant to Alzheimer’s disease (AD), but high‑quality, consistent ...
Lecanemab and donanemab are monoclonal anti‑amyloid antibodies approved for early Alzheimer’s disease that produce modest slowing of decline but carry important and common safety risks—most notably am...
By 2023, a convergence of large observational cohorts, global reviews and early randomized studies strengthened the case that lifestyle matters for Alzheimer’s risk: combined healthy behaviors — regul...